All In Biotech

Drug Trial Radar · NCT05715320

Study of CM310 Injection in Subjects With Moderate-to-Severe Atopic Dermatitis

A Randomized, Double Blind, Parallel-controlled Phase 2 Study to Evaluate the Efficacy and Safety of CM310 Recombinant Humanized Monoclonal Antibody Injection in Subjects With Moderate-to-severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Oct 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

160

Actual

Start

Mar 10, 2023

Primary completion

Jul 18, 2024

Study completion Jul 18, 2024

Sponsor

Lead sponsor
Keymed Biosciences Co.LtdIndustry
Sponsor type
Industry
First posted
Feb 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multi-center, randomized, double-blind, parallel controlled phase 2 study, aimed at evaluating the efficacy and safety of CM310 in the treatment of patients with moderate-to-severe atopic dermatitis, and observing Pharmacokinetics characteristics, Pharmacodynamics effects and immunogenicity.

Conditions

  • Atopic Dermatitis

Interventions

  • CM310Biological

    IL-4Rα monoclonal antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects achieving EASI-75Time frame: up to week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hangzhou First People's Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.